Wie hoch ist der Preis für Opus Genetics, Inc. (IRD)

Preis für Opus Genetics, Inc. (IRD) ist $3.70

Wie hoch ist die Marktkapitalisierung für Opus Genetics, Inc. (IRD)

Marktkapitalisierung für Opus Genetics, Inc. (IRD) ist $305.87M

Opus Genetics, Inc. (IRD) Kursverlauf

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Jahr	Leistung
2026 (TTM)	51.09%
2025	96.16%
2024	0.00%

Jahr

Leistung

2026 (TTM)

51.09%

2025

96.16%

2024

0.00%

Unternehmen	Aktienkurs	Veränderung 1J%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$548.15	40.18%	US
Argenx SE ARGX.US	$1.03K	44.14%	NL
Moderna, Inc. MRNA.US	$153.87	538.73%	US
CSL Limited CSL.AX	$121.37	-11.93%	AU
Lonza Group AG LONN.SW	$748.60	4.92%	CH

Unternehmen

Aktienkurs

Veränderung 1J%

Land